Improving quality of care for patients with recurrent ovarian cancer

• Conditions: cancer of the ovary; Ovarian cancer; 10038594

• Registration Number: NL-OMON45807
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

• Patients with recurrent EOC or tubal carcinoma or peritoneal carcinoma;
• Histologically and/or cytologically proven epithelial ovarian cancer (including carcinosarcoma of the ovaries)
• Measurable or evaluable disease confirmed by radiological imaging OR ca 125
• ECOG <=2
• Estimated life expectancy >=12 weeks
• Patients must be accessible for treatment and follow-up
• Fit to receive chemotherapy

Exclusion Criteria

• Patients with benign ovarian cancer;
• Patients with non-epithelial cancer;
• Bowel obstruction, sub-occlusive disease or presence of symptomatic brain metastases;
• Patients with other malignancy occurring within 5 years before enrollment
• Patients with impaired cognitive functioning or analphabetic patients
• Patients with an inability to fill in surveys digitally

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>the velocity of disease symptom relief and its duration by systemic therapy<br /><br>measured by questionnaires on PROs and response to therapy. Primary endpoints:<br /><br>changes in outcomes on QoL and symptoms due to disease and treatment. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Petient reported disease symptoms top 3, response to therapy as measured by<br /><br>CA-125 and radiology, distress, emotional wellbeing, Empowerment and change in<br /><br>patient reported needs.</p><br>